Petronovic personal page - To The Moon

Petronovic

No personal profile

105Follow

2Followers

4Topic

0Badge

08-23

Great article, would you like to share it?

Sorry, the original content has been removed

06-11

Looks to have merit but presumably expensive to get unless listed on PBS.

Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis

04-22

The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh

Prediction: Palantir's Stock Will Make a Huge Move After May 5

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4145104526174422","uuid":"4145104526174422","gmtCreate":1682002565520,"gmtModify":1682512383681,"name":"Petronovic","pinyin":"petronovic","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":105,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006}],"userBadgeCount":2,"currentWearingBadge":{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":8,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":470612131315960,"gmtCreate":1755932920631,"gmtModify":1755934514027,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/470612131315960","repostId":"2561340272","repostType":2,"isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":444948927574240,"gmtCreate":1749648629323,"gmtModify":1749648661880,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"Looks to have merit but presumably&nbsp; expensive to get unless listed on PBS.","listText":"Looks to have merit but presumably&nbsp; expensive to get unless listed on PBS.","text":"Looks to have merit but presumably expensive to get unless listed on PBS.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/444948927574240","repostId":"2542852885","repostType":2,"repost":{"id":"2542852885","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1749639568,"share":"https://ttm.financial/m/news/2542852885?lang=en_US&edition=fundamental","pubTime":"2025-06-11 18:59","market":"nz","language":"en","title":"Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2542852885","media":"Reuters","summary":"Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu  in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology  Congress in Barcelona, Spain, from June 11-14, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informati","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4559":"巴菲特持仓","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4588":"碎股","BMY":"施贵宝","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4007":"制药","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0237698245.USD":"富达环球地产基金A","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL5PQk2s:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2542852885","content_text":"Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    \n\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"BMY":0.9}},"isVote":1,"tweetType":1,"viewCount":759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":427114298618056,"gmtCreate":1745296664519,"gmtModify":1745296989390,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","listText":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","text":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/427114298618056","repostId":"2529087472","repostType":2,"repost":{"id":"2529087472","kind":"highlight","pubTimestamp":1745290172,"share":"https://ttm.financial/m/news/2529087472?lang=en_US&edition=fundamental","pubTime":"2025-04-22 10:49","market":"us","language":"en","title":"Prediction: Palantir's Stock Will Make a Huge Move After May 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2529087472","media":"Motley Fool","summary":"Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.$Palantir Technologies$ may be one of the most polarizing AI stocks on the market. Some swear by it, and others wouldn't touch it with a 10-foot pole. I'm usually in the 10-foot pole camp, but I would happily change my stance if the stock returned to a reasonable level.After the most recent round of sell-offs, Palantir stock is around 25% ","content":"<div>\n<p>Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.Palantir Technologies may be one of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: Palantir's Stock Will Make a Huge Move After May 5</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: Palantir's Stock Will Make a Huge Move After May 5\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-22 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.Palantir Technologies may be one of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4023":"应用软件","BK4543":"AI","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","PLTR":"Palantir Technologies Inc.","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4547":"WSB热门概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4613":"AI应用软件"},"source_url":"https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2529087472","content_text":"Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.Palantir Technologies may be one of the most polarizing AI stocks on the market. Some swear by it, and others wouldn't touch it with a 10-foot pole. I'm usually in the 10-foot pole camp, but I would happily change my stance if the stock returned to a reasonable level.After the most recent round of sell-offs, Palantir stock is around 25% off its all-time high. This is a pretty significant discount to where it was trading, but is it enough to warrant buying the stock before Palantir reports Q1 earnings on May 5?Palantir's stock has seen big movements following earnings latelyOne thing I'm fairly certain of is that Palantir's stock will likely make a large move on the day following earnings; the question is whether that move will be up or down. For three of its four 2024 quarters, Palantir's stock moved up following earnings. But all four saw double-digit movements.QuarterDate After EarningsPrice MovementQ15/7/2024(15%)Q28/6/202410%Q311/5/202523%Q42/4/202524%Data source: YCharts and Palantir.So, which way will Palantir's stock move after its Q1 earnings report on May 5?The bull case: Palantir has a history of beating expectationsPalantir's management team typically under-guides revenue and over-delivers in the actual announcement. This is far better than the alternative, so I won't dock any points because of management's strategy.Management predicts 36% growth for Q1, the exact same rate it posted during Q4. Historically, investors should expect a percentage point or two higher than this, but we'll see what management delivers.Even more important than that is Palantir's outlook, which could be harmed by economic sentiment. It's no secret that Palantir's software isn't cheap. This is evidenced by the fact that it only has 711 total commercial customers, which generated $372 million in revenue during Q4. If you annualize that figure and divide it by the customer count, you get an average customer value of $2.09 million, which excludes many companies from using Palantir's product.However, if Palantir's potential customers see this software as mission-critical and a way to drive efficiencies, then it could be a no-brainer spending item, contributing to Palantir's management giving upbeat guidance for the rest of the year.While this is the bull case for Palantir and one that I mostly agree will come true, the valuation is just too high for me, so I think the stock will move lower following Q1's earnings announcement.The bear case: Palantir's stock is overpricedAlthough it's a rare position, I'm bullish on Palantir as a company but bearish on its stock. The company trades at a sky-high premium, even after the marketwide sell-off that tanked its stock.PLTR PE Ratio (Forward) data by YChartsFigures of 167 times forward earnings and 79 times sales are outrageous price tags for any stock, let alone one that's only expected to grow revenue by 36% in the quarter.Most software companies trade between 10 and 20 times sales, so Palantir's nearly 80 times sales is absurd. This price tag might be justifiable if Palantir doubled or tripled its revenue each quarter, but it hasn't.This price tag indicates that years of growth have already been priced into the stock. For Palantir to return to the high end of where most software companies trade at (20 times sales), Palantir's revenue would need to grow at a 40% pace for over four years. Keep in mind that's with a growth rate far higher than management predicts, and the stock price not rising.As a result, I think Palantir's stock will sell off following Q1 earnings. The expectations built into the stock are just too high to warrant it rising any higher in an environment where economic fear and pessimism are rampant. There are plenty of other stocks that look like great deals right now, and Palantir should be the last place investors look.","news_type":1,"symbols_score_info":{"PLTR":1}},"isVote":1,"tweetType":1,"viewCount":1127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":427114298618056,"gmtCreate":1745296664519,"gmtModify":1745296989390,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","listText":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","text":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/427114298618056","repostId":"2529087472","repostType":2,"repost":{"id":"2529087472","kind":"highlight","pubTimestamp":1745290172,"share":"https://ttm.financial/m/news/2529087472?lang=en_US&edition=fundamental","pubTime":"2025-04-22 10:49","market":"us","language":"en","title":"Prediction: Palantir's Stock Will Make a Huge Move After May 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2529087472","media":"Motley Fool","summary":"Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.$Palantir Technologies$ may be one of the most polarizing AI stocks on the market. Some swear by it, and others wouldn't touch it with a 10-foot pole. I'm usually in the 10-foot pole camp, but I would happily change my stance if the stock returned to a reasonable level.After the most recent round of sell-offs, Palantir stock is around 25% ","content":"<div>\n<p>Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.Palantir Technologies may be one of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: Palantir's Stock Will Make a Huge Move After May 5</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: Palantir's Stock Will Make a Huge Move After May 5\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-22 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.Palantir Technologies may be one of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4023":"应用软件","BK4543":"AI","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","PLTR":"Palantir Technologies Inc.","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4547":"WSB热门概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4613":"AI应用软件"},"source_url":"https://www.fool.com/investing/2025/04/21/prediction-palantirs-stock-will-make-a-huge-move-a/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2529087472","content_text":"Palantir's stock moved at a double-digit rate in each of the last four earnings reports.The stock has a premium valuation that will hamper any upward movement.Palantir Technologies may be one of the most polarizing AI stocks on the market. Some swear by it, and others wouldn't touch it with a 10-foot pole. I'm usually in the 10-foot pole camp, but I would happily change my stance if the stock returned to a reasonable level.After the most recent round of sell-offs, Palantir stock is around 25% off its all-time high. This is a pretty significant discount to where it was trading, but is it enough to warrant buying the stock before Palantir reports Q1 earnings on May 5?Palantir's stock has seen big movements following earnings latelyOne thing I'm fairly certain of is that Palantir's stock will likely make a large move on the day following earnings; the question is whether that move will be up or down. For three of its four 2024 quarters, Palantir's stock moved up following earnings. But all four saw double-digit movements.QuarterDate After EarningsPrice MovementQ15/7/2024(15%)Q28/6/202410%Q311/5/202523%Q42/4/202524%Data source: YCharts and Palantir.So, which way will Palantir's stock move after its Q1 earnings report on May 5?The bull case: Palantir has a history of beating expectationsPalantir's management team typically under-guides revenue and over-delivers in the actual announcement. This is far better than the alternative, so I won't dock any points because of management's strategy.Management predicts 36% growth for Q1, the exact same rate it posted during Q4. Historically, investors should expect a percentage point or two higher than this, but we'll see what management delivers.Even more important than that is Palantir's outlook, which could be harmed by economic sentiment. It's no secret that Palantir's software isn't cheap. This is evidenced by the fact that it only has 711 total commercial customers, which generated $372 million in revenue during Q4. If you annualize that figure and divide it by the customer count, you get an average customer value of $2.09 million, which excludes many companies from using Palantir's product.However, if Palantir's potential customers see this software as mission-critical and a way to drive efficiencies, then it could be a no-brainer spending item, contributing to Palantir's management giving upbeat guidance for the rest of the year.While this is the bull case for Palantir and one that I mostly agree will come true, the valuation is just too high for me, so I think the stock will move lower following Q1's earnings announcement.The bear case: Palantir's stock is overpricedAlthough it's a rare position, I'm bullish on Palantir as a company but bearish on its stock. The company trades at a sky-high premium, even after the marketwide sell-off that tanked its stock.PLTR PE Ratio (Forward) data by YChartsFigures of 167 times forward earnings and 79 times sales are outrageous price tags for any stock, let alone one that's only expected to grow revenue by 36% in the quarter.Most software companies trade between 10 and 20 times sales, so Palantir's nearly 80 times sales is absurd. This price tag might be justifiable if Palantir doubled or tripled its revenue each quarter, but it hasn't.This price tag indicates that years of growth have already been priced into the stock. For Palantir to return to the high end of where most software companies trade at (20 times sales), Palantir's revenue would need to grow at a 40% pace for over four years. Keep in mind that's with a growth rate far higher than management predicts, and the stock price not rising.As a result, I think Palantir's stock will sell off following Q1 earnings. The expectations built into the stock are just too high to warrant it rising any higher in an environment where economic fear and pessimism are rampant. There are plenty of other stocks that look like great deals right now, and Palantir should be the last place investors look.","news_type":1,"symbols_score_info":{"PLTR":1}},"isVote":1,"tweetType":1,"viewCount":1127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":470612131315960,"gmtCreate":1755932920631,"gmtModify":1755934514027,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/470612131315960","repostId":"2561340272","repostType":2,"isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":444948927574240,"gmtCreate":1749648629323,"gmtModify":1749648661880,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"Looks to have merit but presumably&nbsp; expensive to get unless listed on PBS.","listText":"Looks to have merit but presumably&nbsp; expensive to get unless listed on PBS.","text":"Looks to have merit but presumably expensive to get unless listed on PBS.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/444948927574240","repostId":"2542852885","repostType":2,"repost":{"id":"2542852885","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1749639568,"share":"https://ttm.financial/m/news/2542852885?lang=en_US&edition=fundamental","pubTime":"2025-06-11 18:59","market":"nz","language":"en","title":"Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2542852885","media":"Reuters","summary":"Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu  in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology  Congress in Barcelona, Spain, from June 11-14, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informati","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4559":"巴菲特持仓","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4588":"碎股","BMY":"施贵宝","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4007":"制药","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0237698245.USD":"富达环球地产基金A","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL5PQk2s:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2542852885","content_text":"Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    \n\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"BMY":0.9}},"isVote":1,"tweetType":1,"viewCount":759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}